Pipelines & Targets

We strive to develop innovative therapies by strategically focusing on genetically defined diseases. Our clinical pipeline is focused on bezuclastinib, a highly selective and potent KIT inhibitor with the potential to provide a real solutions for patients. Our research pipeline leverages our world-class research and development team to advance our preclinical assets.

Clinical Programs
Research Programs


With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.

Scroll to Top